


Curriculum Vitae

 Photo	Name (First Name, Middle Name Last Name)	Corey Allan Siegel
	Position	Section Chief, Gastroenterology and Hepatology Constantine and Joyce Hampers Professor of Medicine
	Affiliation	Dartmouth-Hitchcock Medical Center Geisel School of Medicine at Dartmouth
	Country	USA
	Major Field	Inflammatory Bowel Disease

Education Background	
EDUCATION	
2007-2009	M.S., Clinical/Health Services Research, The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
1994-1998	M.D., Tufts University School of Medicine, Boston, Massachusetts
1989-1993	B.S., Tufts University College of Liberal Arts, Medford, Massachusetts
POSTDOCTORAL TRAINING	
2004-2005	Advanced Fellowship in Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, Massachusetts Mentors: Dr. Bruce E. Sands & Dr. Joshua R. Korzenik
2002-2005	Fellow in Gastroenterology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
2001-2002	Chief Medical Resident, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
1999-2001	Resident, Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
1998-1999	Intern, Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire



Professional Experience

ACADEMIC APPOINTMENTS

- 2021-present Constantine and Joyce Hampers Professor of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH
- 2019-present Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, NH
- 2012-present Associate Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, NH
- 2012-2017 Adjunct faculty, White River Junction VA Outcomes Group
- 2010-2012 Assistant Professor, Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover NH
- 2005-2012 Assistant Professor of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH
- 2004-2005 Clinical and Research Fellow in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA

HOSPITAL APPOINTMENTS

- 2017-present Section Chief, Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- 2012-2014, 2018-present Medical Director, Medical Infusion Services, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- 2011-present Director, Gastroenterology and Hepatology Research Program, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
- 2005-present Director (Co-Director as of January 2018), Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Professional Organizations

PROFESSIONAL SOCIETY MEMBERSHIPS

- American College of Gastroenterology
- American Gastroenterological Association
- American Telemedicine Association
- Crohn's and Colitis Foundation

Scientific Publication

Original Publications

1. Barnes EL, Hanson JS, Regueiro MD, Saha S, Sands BE, Rubin DT, Dubinsky MC, **Siegel CA**, Gazis DR, Crawford JM, Long MD. Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD..J Clin Gastroenterol. 2021 Jun 11. Online ahead of print.
2. Oliver BJ, Kennedy AM, van Deen WK, Weaver SA, Heller C, Holthoff MM, Bank J, Melmed GY, **Siegel CA**, Nelson EC. Development of Balanced Whole System Value Measures for

Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process. *Inflamm Bowel Dis*. 2021 May 25. Online ahead of print.

3. Kim AH, Girgis A, De Cruz P, **Siegel CA**, Karimi N, Ruban SO, Sechi AJ, Ng WSW, Andrews JM, Connor SJ. Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. *J Med Internet Res*. 2021 Feb 25;23(2):e15946.
4. Long MD, **Siegel CA**, Abraham BP, Chiorean M, Mahadevan U. Day Care Attendance and Infectious Complications in Children Born to Mothers with Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol*. 2021. Online ahead of print.
5. **Siegel CA**, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC; International Organization for the Study of Inflammatory Bowel Disease (IOIBD). SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. *Gut*. 2021 Apr;70(4):635-640.
6. Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, **Siegel CA**. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2020. Online ahead of print.
7. Falling C, Stebbings S, Baxter GD, **Siegel CA**, Geary RB, Nijs J, Mani R. Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors. *Scand J Pain*. 2020. Online ahead of print.
8. Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwaniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Kolianni-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV Jr, Sands BE, Colombel JF, **Siegel CA**, Sandborn WJ, Dulai PS. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2020 Oct 8:S1542-3565(20)31388-4.
9. Dulai PS, Raffals LE, Hudesman D, Chiorean M, Cross R, Ahmed T, Winter M, Chang S, Fudman D, Sadler C, Chiu EL, Ross FL, Toups G, Murad MH, Sethuraman K, Holm JR, Guillod R, Levine B, Buckley JC Jr, **Siegel CA**. A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. *Aliment Pharmacol Ther*. 2020 Sep;52(6):955-963.
10. Kim AH, Girgis A, Karimi N, Sechi AJ, Descallar J, Andrews JM, **Siegel CA**, Connor SJ A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial. *JMIR Res Protoc*. 2020 Jul 10;9(7):e15994.
11. Bohm M, Xu R, Zhang Y, Varma S, Fischer M, Kochhar G, Boland B, Singh S, Hirten R, Ungaro R, Shmidt E, Lasch K, Jairath V, Hudesman D, Chang S, Lukin D, Swaminath A, Sands BE, Colombel JF, Kane S, Loftus EV Jr, Shen B, **Siegel CA**, Sandborn WJ, Dulai PS; VICTORY Collaboration. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. *Aliment Pharmacol Ther*. 2020 Aug;52(4):669-681.

12. **Siegel CA**, Yang F, Eslava S, Cai Z. Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn's disease in the United States. *Clin Transl Gastroenterol.* 2020;11(2):e00128.
13. Coburn ES, **Siegel CA**, Winter M, Shah ED. Hemophagocytic Lymphohistiocytosis Occurring in Inflammatory Bowel Disease: Systematic Review. *Dig Dis Sci.* 2021 Mar;66(3):843-854.
14. van Deen WK, Kiaei B, Weaver SA, Crate DJ, Kwon MH, Shah SA, Melmed GY, **Siegel CA**. A qualitative inquiry into patients' perspectives on individualized priorities for treatment outcomes in inflammatory bowel diseases. *Qual Life Res.* 2020 Sep;29(9):2403-2414
15. Rubin DT, Abreu MT, Rai V, **Siegel CA**. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting.; International Organization for the Study of Inflammatory Bowel Disease. *Gastroenterology.* 2020 Jul;159(1):6-13
16. Papamichael K, Clarke WT, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, **Siegel CA**, Irving PM, Cheifetz AS. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol.* 2021 Apr;19(4):839-841.
17. Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, Aniwani S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, **Siegel CA**, Shen B, Kane S, Loftus EV Jr, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol.* 2020 Dec;18(13):2952-2961.
18. Shah ED, Coburn ES, Nayyar A, Lee KJ, Koliani-Pace JL, **Siegel CA**. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. *Aliment Pharmacol Ther.* 2020 Mar;51(5):527-533.
19. Danese S, Neurath MF, Kopoń A, Zakko SF, Simmons TC, Fogel R, **Siegel CA**, Panaccione R, Zhan X, Usiskin K, Chitkara D Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. *Clin Gastroenterol Hepatol.* 2020 Oct;18(11):2526-2534
20. **Siegel CA**, Thompson KD, Walls D, Gollins J, Buisson A, Olympie A, Beaugerie L, Colombel JF, Louis E; BIOCYCLE group. Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease. *Clin Gastroenterol Hepatol.* 2021 Feb;19(2):403-405.
21. Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, **Siegel CA**, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. *Collaboration* Aliment Pharmacol Ther.* 2020 Mar;51(5):553-564.

22. Clarke WT, Papamichael K, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, **Siegel CA**, Irving PM, Cheifetz AS. Infiximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. *Inflamm Bowel Dis.* 2019 Oct 18;25(11):e143-e145
23. Koliani-Pace JL, Haron AM, Zisman-Ilani Y, Thompson KD, **Siegel CA**. Patients' Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications. *Inflamm Bowel Dis.* 2020 Jan 1;26(1):141-146.
24. Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, **Siegel CA**, Dulai PS. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. *Inflamm Bowel Dis.* 2019 Oct 18;25(11):1854-1861.
25. Sparrow MP, Melmed GY, Devlin D, Kozuch P, Raffals L, Loftus Jr EV, Rubin DT, Spiegel B, Baidoo L, Bressler B, Cheifetz A, Irving P, Jones J, Kaplan GG, Velayos F, **Siegel CA**. De-escalating medical therapy in Crohn's disease patients who are in deep remission: A RAND appropriateness panel. *GastroHep* May 2019; 1(3): 108-117.
26. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Casteele NV, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, **Siegel CA**. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol.* 2019. 17(9):1655-1668.
27. Rubin DT, Ananthakrishnan AN, **Siegel CA**, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol.* 2019 Mar;114(3):384-413.
28. Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, **Siegel CA**, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. *Clin Gastroenterol Hepatol.* 2019;17:2497.
29. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, **Siegel CA**, Sandborn WJ, Dulai PS. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol.* 2019;17:1533.
30. Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, **Siegel CA**, Reinisch W, Greenbaum LE. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. *Gastroenterology.* 2018 Oct;155(4):1008-1011.

31. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, **Siegel CA**, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. *Am J Gastroenterol*. 2018 Sep;113(9):1345.
32. Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, **Siegel CA**, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. *Gastroenterology*. 2018 Sep;155(3):687-695.
33. Schreiber S, **Siegel CA**, Friedenber KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundry JS, Lee SD, Loftus EV Jr. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andexcaliximab, in Patients with Moderate to Severely Active Crohn's Disease. *J Crohns Colitis*. 2018. Epub ahead of print.
34. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, **Siegel CA**, Sands BE, Colombel JF, Shen B, Dulai PS. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2018 Oct 12;24(11):2461-2467.
35. Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, **Siegel CA**, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review for Development of a Core Outcome Set. *Clin Gastroenterol Hepatol*. 2018;16(9):1407-1419.
36. Lo B, Vester-Andersen MK, Vind I, Prosberg M, Dubinsky M, **Siegel CA**, Bendtsen F, Burisch J. Changes in Disease Behaviour and Location in Patients With Crohn's Disease After Seven Years of Follow-Up: A Danish Population-based Inception Cohort. *J Crohns Colitis*. 2018 Feb 28;12(3):265-272.
37. Melmed GY, Kaplan GG, Sparrow MP, Velayos FS, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Irving PM, Jones J, Kozuch PL, Raffals LE, **Siegel CA**. Appropriateness of Combination Therapy in Inflammatory Bowel Disease: One Size Still Does Not Fit All. *Clin Gastroenterol Hepatol*. 2018. Epub ahead of print.
38. Dulai PS, Buckey JC Jr., Raffals LE, Swoger JM, Claus PL, O'Toole K, Ptak JA, Gleeson MW, Widjaja CE, Chang JT, Adler JM, Patel N, Skinner LA, Haren SP, Goldby-Reffner K, Thompson KD, **Siegel CA**. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. *Am J Gastroenterol*. 2018. Epub ahead of print.

39. Grossberg LB, Papamichael K, Feuerstein JD, **Siegel CA**, Ullman TA, Cheifetz AS. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2017 Dec 19;24(1):191-197.
40. Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, **Siegel CA**, Terry H, van Deen WK, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP. Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. *J Crohns Colitis*. 2018 Mar 28;12(4):408-418.
41. Parker S, Zipursky J, Ma H, Baumblatt GL, **Siegel CA**. A Web-based Multimedia Program Before Colonoscopy Increased Knowledge and Decreased Anxiety, Sedation Requirement, and Procedure Time. *J Clin Gastroenterol*. 2017. Epub ahead of print.
42. Asl Baakhtari S, McCombie A, Ten Bokkel Huinink S, Irving P, **Siegel CA**, Mulder R, Mulder CJ, Geary R. Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. *Dig Dis*. 2018;36(1):33-39.
43. **Siegel CA**, Whitman CB, Spiegel BM, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D'Haens G, Bernstein CN, Geary R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DP, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Development of an index to define overall disease severity in IBD. *Gut* 2018;67:244-254.
44. Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, **Siegel CA**, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. *Clin Gastroenterol Hepatol*. 2017. Epub ahead of print.
45. Li SX, Thompson KD, Peterson T, Huneven S, Carmichael J, Glazer FJ, Darling K, **Siegel CA**. Delivering High Value Inflammatory Bowel Disease Care Through Telemedicine Visits. *Inflamm Bowel Dis*. 2017 Oct;23(10):1678-1681.
46. Shah ED, Farida JP, **Siegel CA**, Chong K, Melmed GY. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. *Inflamm Bowel Dis*. 2017 Apr;23(4):570-577.
47. Picoraro J, Winberry G, **Siegel CA**, El-Matary W, Moses J, Grossman A, Park KT. Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. *Inflamm Bowel Dis*. 2017 Jan;23(1):174-180.
48. Hou JK, Gasche C, Drazin NZ, Weaver SA, Ehrlich OG, Oberai R, Zapala S, **Siegel CA**, Melmed G. Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases. *Inflamm Bowel Dis*. 2017;23:35-43.
49. Tinsley A, Ehrlich OG, Hwang C, Issokson K, Zapala S, Weaver A, **Siegel CA**, Melmed GY. Knowledge, Attitudes, and Beliefs Regarding the Role of Nutrition in IBD Among Patients and Providers. *Inflamm Bowel Dis*. 2016;22:2474-81.

50. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, **Siegel CA**, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. *Am J Gastroenterol*. 2016;111:1147-55.
51. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, **Siegel CA**. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. *Clin Gastroenterol Hepatol*. 2016;13:1302-9.
52. Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, **Siegel CA**. Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. *Inflamm Bowel Dis*. 2016;22:1418-22.
53. Lennerz JK, van der Sloot KW, Le LP, Batten JM, Han JY, Fan KC, **Siegel CA**, Srivastava A, Park do Y, Chen JH, Sands BE, Korzenik JR, Odze RD, Dias-Santagata D, Borger DR, Khalili H, lafrate AJ, Lauwers GY. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. *Int J Colorectal Dis*. 2016;31:973-82.
54. Thompson KD, Connor SJ, Walls DM, Gollins J, Stewart SK, Bewtra M, Baumblatt GL, Holubar SD, Greenup AJ, Sechi A, Girgis A, Rubin DT, **Siegel CA**. Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. *Inflamm Bowel Dis* 2016;22:940-7.
55. Shah ED, **Siegel CA**, Chong K, Melmed GY. Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials. *Inflamm Bowel Dis*. 2016;22:933-9.
56. **Siegel CA**, Horton H, Siegel LS, Thompson KD, Mackenzie T, Stewart SK, Rice PW, Stempak JM, Dezfoli S, Haritunians T, Levy A, Baek M, Milgrom R, Dulai PS, Targan SR, Silverberg MS, Dubinsky MC, McGovern DP. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. *Aliment Pharmacol Ther*. 2016;43:262-271.
57. Siegel CA, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients' Perspectives on Shared Decision Making. *Patient*. 2016;9:79-89.
58. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Geary R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, **Siegel CA**, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. [Selecting Therapeutic Targets in Inflammatory Bowel Disease \(STRIDE\): Determining Therapeutic Goals for Treat-to-Target](#). *Am J Gastroenterol*. 2015 Sep;110(9):1324-38.

59. Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, **Siegel CA**. [Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials](#). Clin Gastroenterol Hepatol. 2015;13:2233-40.
60. Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, **Siegel CA**, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. [Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECISE 3 study](#). Aliment Pharmacol Ther. 2015 Aug;42(3):330-42.
61. **Siegel CA**, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Gastroenterologists' Views of Shared Decision Making for Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2015 Sep;60(9):2636-45.
62. Shah ED, **Siegel CA**, Chong K, Melmed GY. [Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability](#). Dig Dis Sci. 2015 Aug;60(8):2408-18.
63. Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, Kuenzig E, Tomlinson G, **Siegel CA**, Melmed GY, Kaplan GG. [Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis](#). Gastroenterology. 2015 Feb;148(2):344-54.
64. Dulai PS, **Siegel CA**, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. Systematic review: Monotherapy with antitumor necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014 Dec;63(12):1843-53.
65. Bewtra M, Brensinger CM, Tomov VT, Hoang TB, Sokach CE, **Siegel CA**, Lewis JD. [An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index](#). Inflamm Bowel Dis. 2014 Jun;20(6):1070-8.
66. Dulai PS, Gleeson MW, Taylor D, Holubar SD, Buckey JC, **Siegel CA** [Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease](#). Aliment Pharmacol Ther. 2014 Jun;39(11):1266-75.
67. Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, **Siegel CA**. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1443-51.
68. Bewtra M, Kilambi V, Fairchild AO, **Siegel CA**, Lewis JD, Johnson FR. Patient preferences for surgical versus medication therapy for ulcerative colitis. Inflamm Bowel Dis. 2014 Jan;20(1):103-1.
69. Parker S, Chambers White L, Spangler C, Rosenblum J, Sweeney S, Homan E, Bensen SP, Levy LC, Dragnev MC, Moskalenko-Locke K, Rich P, **Siegel CA**. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis. 2013 Aug;19(9):1809-14.

70. Melmed GY, **Siegel CA**, Spiegel BM, Allen JI, Cima R, Colombel JF, Dassopoulos T, Denson LA, Dudley-Brown S, Garb A, Hanauer SB, Kappelman MD, Lewis JD, Lynch I, Moynihan A, Rubin DT, Sartor RB, Schwartz RM, Wolf DC, Ullman TA. Quality indicators for inflammatory bowel disease: development of process and outcome measures. *Inflamm Bowel Dis*. 2013 Mar;19(3):662-8.
71. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, **Siegel CA**, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2013 Mar;11(3):286-92.
72. Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, **Siegel CA**. Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert RAND panel, and patient focus groups. *Inflamm Bowel Dis* 2012;18:2294.
73. Ha C. Ullman TA, **Siegel CA**, Kornbluth A. Patients enrolled in randomized clinical trials do not represent the inflammation bowel disease patient population. *Clin Gastroenterol Hepatol* 2012;10:1002.
74. Lacy BE, Everhart KK, Weiser KT, Delee R, Strobel S, **Siegel C**, Croweel MD. IBS patients' willingness to take risks with medications. *Am J Gastroenterol* 2012;107(6):804-809.
75. **Siegel CA**, Finlayson SR, Sands BE, Tosteson AN. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. *Clin Gastroenterol Hepatol*. 2012;10(1):46-51.
76. Ashworth LA, Billett A, Mitchell P, Nuti F, **Siegel C**, Bousvaros A. Lymphoma risk in children and young adults with inflammatory bowel disease; Analysis of a large single-center cohort. *Inflamm Bowel Dis* 2012;18(5):838-43.
77. Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, **Siegel CA**, Sandborn WJ, Travis SP, Colombel JF. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: Safety. *Am J Gastroenterol* 2011;106(9):1594-602.
78. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quarry A, Sands B, Sood A, Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, **Siegel C**, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. [The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?](#) *Am J Gastroenterol*, 2011;106:199-212.
79. **Siegel CA**, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, Crandall W, Evans J, Keljo DJ, Otlely AR, Oliva-Hemker M, Farrior S, Langton CR, Wrobel IT, Wahbeh G, Quiros JA, Silber G, Bahar RJ, Sands BE, Dubinsky MC. A Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. *Inflamm Bowel Dis* 2011; 17:30-8.

80. Johnson FR, Hauber B, Ozdemir S, **Siegel CA**, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit risk preferences in Crohn's disease management. *J Manag Care Pharm.* 2010;16:616.
81. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, **Siegel CA**. The appropriateness of concomitant immunomodulators and anti-TNF agents for Crohn's disease: One size does not fit all. *Clin Gastroenterol Hepatol* 2010; 8:655.
82. Baars JE, **Siegel CA**, Van't Spijker A, Markus T, Kuipers EJ, van der Woude CJ. Inflammatory bowel disease patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. *Dig Liver Dis* 2010;42:777-784.
83. **Siegel CA**, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. *Inflamm Bowel Dis* 2010;16:1658-62.
84. Rubin DT, Dubinsky MC, Panaccione R, **Siegel CA**, Binion DG, Kane SV, Hopper J. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: A patient survey. *Dig Dis Sci.* 2010; 55:1044.
85. Wilcox AR, Dragnev C, Darcey CJ, **Siegel CA**. A new tool to measure the burden of Crohn's disease and its treatment: Do patient and physician perceptions match? *Inflamm Bowel Dis* 2010;16:645.
86. Awais D, **Siegel CA**, Higgins PD. Modeling dysplasia detection in ulcerative colitis: Clinical implications of surveillance intensity. *Gut* 2009;58:1498.
87. **Siegel CA**, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of Lymphoma Associated with Combination Anti-TNF and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis. *Clinical Gastroenterology and Hepatology* 2009;7:874. *NOTE – this manuscript was in the "Top 10" most cited manuscripts in this journal from 2008-2010.
88. Courville EL, **Siegel CA**, Vay T, Wilcox AR, Suriawinata AA, Srivastava A. Isolated Asymptomatic Ileitis Does Not Progress To Overt Crohn's Disease On Long Term Follow Up Despite Features Of Chronicity In Ileal Biopsies. *Am J Surg Pathol* 2009;33:1341.
89. Baars JE, **Siegel CA**, Kuipers EJ, van der Woude CJ. Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. *Digestion* 2009;79:30-35.
90. Rubin DT, **Siegel CA**, Kane SV, Binion DG, Panaccione R, Dubinsky MC, Loftus EV, Hopper J. Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. *Inflamm Bowel Dis.* 2009 Apr;15(4):581-8..
91. Johnson FR, Ozdemir S, Mansfield C, Hass S, **Siegel CA**, Sands BE. Are adult patients more tolerant of treatment risks than parents of juvenile patients? *Risk Analysis* 2009;29(1):121-136.
92. Spiegel BM, Ho W, Esrailian E, Targan S, Higgins P, **Siegel CA**, Dubinsky M, Melmed G. Controversies in ulcerative colitis: A survey comparing decision making of experts versus community gastroenterologists. *Clin Gastroenterol Hepatol* 2008;7(2):169-74.

93. **Siegel CA**, Levy LC, Mackenzie, Sands BE. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. *Inflamm Bowel Dis* 2008;14(1): 1-6.
94. Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, **Siegel CA**, Sands, BE. Crohn's Disease Patients' Benefit-Risk Preferences: Serious Adverse Event Risks versus Treatment Efficacy. *Gastroenterology* 2007;133(3):769-79.
95. **Siegel CA**, Hur C, Korzenik JR, Gazelle, GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. *Clinical Gastroenterology and Hepatology* 2006;4:1017-1024.
96. **Siegel CA**, Sands BE. Risk factors for colorectal cancer in Crohn's colitis: A case-control study. *Inflammatory Bowel Diseases* 2006;12:491-496.
97. Reddy D, **Siegel CA**, Sands BE, Kane S. Possible association between isotretinoin and inflammatory bowel disease. *Am Journal Gastroenterol* 2006;101:1569-1573.

Review articles

1. **Siegel CA**, Christensen B, Kornbluth A, Rosh JR, Kappelman MD, Ungaro RC, Johnson DF, Chapman S, Wohl DA, Mantzaris GJ Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19.. *J Crohns Colitis*. 2020 Oct 21;14 (Supplement 3): S769-S773.
2. **Siegel CA**. Management of Inflammatory Bowel Disease With Telemedicine. *Gastroenterol Hepatol (N Y)*. 2020 Oct;16(10):526-528.
3. Horrigan JM, **Siegel CA**, Tadros M. Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic. *Inflamm Bowel Dis*. 2020 Oct 23;26(11):e137.
4. Shah ED, **Siegel CA**. Systems-Based Strategies to Consider Treatment Costs in Clinical Practice. *Clin Gastroenterol Hepatol*. 2020 May;18(5):1010-1014
5. **Siegel CA**, Bernstein CN. Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. *Clin Gastroenterol Hepatol*. 2020 May;18(6):1261-1267.
6. Denson LA, Curran M, McGovern DPB, Koltun WA, Duerr RH, Kim SC, Sartor RB, Sylvester FA, Abraham C, de Zoeten EF, **Siegel CA**, Burns RM, Dobes AM, Shtraizent N, Honig G, Heller CA, Hurtado-Lorenzo A, Cho JH. Challenges in IBD Research: Precision Medicine. *Inflamm Bowel Dis*. 2019 May 16;25(Suppl 2):S31-S39.
7. Koliani-Pace JL, **Siegel CA** Prognosticating the Course of Inflammatory Bowel Disease. *Gastrointest Endosc Clin N Am*. 2019 Jul;29(3):395-404
8. **Siegel CA**. Placing Value on Telemedicine for Inflammatory Bowel Disease. *Am J Gastroenterol*. 2019 Mar;114(3):382-383
9. Chandra JA, Regueiro MD, Greer JB, Herfath HH, Clarke K, Williams ED, Cross RK, DeCross AJ, Saubermann LJ, Brand MH, Farraye FA, Shah SA, Keljo DJ, Watson AR, Binion DG, **Siegel CA**.

Non-healing Gluteal Ulceration in a Patient with Crohn's Disease. Accessed 7/2/19:

<https://site.crohnscolitisfoundation.org/science-and-professionals/programs-materials/ibd-live/ibd-live-case-12-2.pdf>

10. Lindholm CR, **Siegel CA**. Are we ready to include prognostic factors in inflammatory bowel disease trials? *Curr Pharm Des.* 2019;25(1):64-68.
11. **Siegel CA**. Placing Value on Telemedicine for Inflammatory Bowel Disease. *Am J Gastroenterol.* 2019;114(3):382-383.
12. **Siegel CA**. Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care. *Am J Gastroenterol.* 2018 Oct;113(10):1440-1443.
13. Volk N, **Siegel CA**, Defining Failure of Medical Therapy for Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2019;25(1):74-77.
14. Proksell SS, Greer JB, Theisen BK, Davis PL, Rosh JR, Keljo DJ, Goyal A, Shah SA, Brand MH, Herfarth HH, Cross RK, **Siegel CA**, Koltun WA, Isaacs KL, Regueiro MD. IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis? *Inflamm Bowel Dis.* 2018 Mar 19;24(4):698-713.
15. Papamichael K, Osterman MT, **Siegel CA**, Melmed GY, Dubinsky MC, Colombel JF, Hanauer SB, Cheifetz AS Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? *Gastroenterology.* 2018 Mar;154(4):1201-1202.
16. Iskandar H, Greer JB, Krasinskas AM, Tinsley AT, Koltun WA, **Siegel CA**, Levy LC, Herfarth HH, Farraye FA, Binion DG, Rosh JR, Keljo DJ, Isaacs KL, Regueiro MD. IBD LIVE Series-Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa. *Inflamm Bowel Dis.* 2017 Oct;23(10):1667-1677.
17. Koliani-Pace JL, **Siegel CA**. Beyond disease activity to overall disease severity in inflammatory bowel disease. *Lancet Gastroenterol Hepatol.* 2017 Sep;2(9):624-626.
18. Berry SK, **Siegel CA**, Melmed GY. Quality Improvement Initiatives in Inflammatory Bowel Disease. *Curr Gastroenterol Rep.* 2017 Aug 19(8):41.
19. Dulai PS, **Siegel CA**. Optimization of drug safety profile in inflammatory bowel disease through a personalized approach. *Curr Drug Targets.* 2017;19:740-747.
20. Click BH, Greer JB, Regueiro MD, Hartman DJ, Davis PL, **Siegel CA**, Herfarth HH, Rosh JR, Shah SA, Koltun WA, Binion DG, Baidoo L, Szigethy E. IBD LIVE Series-Case 7: The Brain-Gut Connection and the Importance of Integrated Care in IBD. *Inflamm Bowel Dis.* 2017 May;23(5):681-694.
21. Click BH, Greer JB, Regueiro MD, Hartman DJ, Davis PL, **Siegel CA**, Herfarth HH, Rosh JR, Shah SA, Koltun WA, Binion DG, Baidoo L, Szigethy E. IBD LIVE Series-Case 7: The Brain-Gut Connection and the Importance of Integrated Care in IBD. *Inflamm Bowel Dis.* 2017 May;23(5):681-694.

22. Johnson LC, Melmed GY, Nelson EC, Holthoff MM, Weaver SA, Morgan TS, **Siegel CA**. Fostering Collaboration Through Creation of an IBD Learning Health System. Am J Gastroenterol. 2017 Mar;112(3):406-408.
23. **Siegel CA**. Transforming Gastroenterology Care With Telemedicine. Gastroenterology. 2017 Apr;152(5):958-963. This publication was the cover story.
24. Rajan D, Greer JB, Regueiro MD, Baidoo L, Binion DG, Herfarth HH, **Siegel CA**, Hartman DJ, Farraye FA, Koutroubakis IE, Brand MH, Williams ED, Goyal A, Cross RK. IBD LIVE Case Series – Case 6. Inflamm Bowel Dis. 2016;22:2754.
25. **Siegel CA**, Jones JL, Kaplan GG. Reply. Clin Gastroenterol Hepatol. 2016;14:914-15.
26. Koliani-Pace J, **Siegel CA**. Is the Hype of Medical Marijuana All Smoke and Mirrors? Am J Gastroenterol. 2016;111:161-2.
27. **Siegel CA**, Dubinsky MC. Editorial: how to interpret risks and prediction of complications in Crohn's disease – can our patients interpret them? Authors' reply. Aliment Pharmacol Ther. 2016;43:653.
28. Stein BN, Pellish RS, Thompson KD, Baptista V, **Siegel CA**. Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis. J Clin Gastroenterol. 2016;50:66-68.
29. Sunseri WM, Kugathasan S, Keljo DJ, Greer JB, Ranganathan S, Cross RK, **Siegel CA**, Regueiro MD. IBD LIVE Case Series-Case 3: Very Early-Onset Inflammatory Bowel Disease: When Genetic Testing Proves Beneficial. Inflamm Bowel Dis. 2015 Dec;21(12):2958-68.
30. Shah SL, **Siegel CA**. Increasing patient activation could improve outcomes for patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;12: 2975-8.
31. Le PN, Greer JB, Oikonomou I, Schraut WH, **Siegel CA**, Cross RK, Holubar SD, Tinsley A, Koltun WA, Binion DG, Regueiro MD. IBD LIVE Case Series-Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis. 2015 Jun;21(6):1401-6.
32. Ahmed S, **Siegel CA**, Melmed GY. [Implementing quality measures for inflammatory bowel disease](#). Curr Gastroenterol Rep. 2015 Apr;17(4):14.
33. Gerich ME, Isfort RW, Brimhall B, **Siegel CA**. [Medical marijuana for digestive disorders: high time to prescribe?](#) Am J Gastroenterol. 2015 Feb;110(2):208-14.
34. Iskandar H, Greer JB, Schraut WH, Regueiro MD, Davis PL, Hartman DJ, **Siegel CA**, Herfarth HH, Williams ED, Schwartz MB. [IBD LIVE case series-case 1: smoking, a controversial but effective treatment for ulcerative colitis](#). Inflamm Bowel Dis. 2014;20:1696-1701.
35. Regueiro MD, Greer JB, Binion DG, Schraut WH, Goyal A, Keljo DJ, Cross RK, Williams ED, Herfarth HH, **Siegel CA**, Oikonomou I, Brand MH, Hartman DJ, Tublin ME, Davis PL, Baidoo L, Szigethy E, Watson AR; IBD LIVE Physician Group. The inflammatory bowel disease live interinstitutional and interdisciplinary videoconference education (IBD LIVE) series. Inflamm Bowel Dis. 2014 Oct;20(10):1687-95.

36. Dulai PS, **Siegel CA**. [The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease.](#) Gastroenterol Clin North Am. 2014 Sep;43(3):525-41.
37. Dulai PS, **Siegel CA**, Peyrin-Biroulet L. Anti-tumor necrosis factor- α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am. 2014 Sep;43(3):441-56.
38. **Siegel CA**. [Patient decision tools in inflammatory bowel disease.](#) Gastroenterol Hepatol (NY). 2013 Sep;9(9):585-7.
39. Danese S, **Siegel CA**, Peyrin-Biroulet L. [Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.](#) Aliment Pharmacol Ther. 2014 May;39(10):1095-103.
40. Bressler B, **Siegel CA**. [Beware of the swinging pendulum: anti-tumor necrosis factor monotherapy vs combination therapy for inflammatory bowel disease.](#) Gastroenterology. 2014 Apr;146(4):884-7.
41. Dulai PS, **Siegel CA**, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2013 Dec;19(13):2927-36.
42. Melmed GY, **Siegel CA**. Quality improvement in inflammatory bowel disease. Gastroenterol Hepatol 2013; 9(5):286-92.
43. **Siegel CA**, Allen JI, Melmed GY. Translating improved quality of care into an improved quality of life. Clin Gastroenterol Hepatol 2013;11(8):908-12.
44. Mason M, **Siegel CA**. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19(6):1306-21.
45. Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, **Siegel CA**, Higgins PD, Herfarth HH, Hyams J, Sandborn WJ, Loftus EV Jr, Kappelman MD, Lewis JD, Parkos CA, Sartor RB; Challenges Workgroup. Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013 Mar-Apr;19(4):677-82.
46. Devlin SM, Cheifetz AS, **Siegel CA**, on behalf of the BRIDGe Group. Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease. Gastroenterol Clin North Am 2012;41(2):411-28.
47. Feuerstein JD, Cheifetz AS, **Siegel CA**. Comparative effectiveness research in inflammatory bowel disease: prospects and challenges. Expert Rev Gastroenterol Hepatol 2012;6:405-407.
48. Levy LC, **Siegel CA**. Commentary: diagnostic medical radiation exposure in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(8):959-60.
49. **Siegel CA**. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut 2012;61(3):459-65.
50. Loew BJ, **Siegel CA**. Foam preparations for the treatment of ulcerative colitis. Current Drug Delivery 2012;9:338-344.

51. **Siegel CA.** Review article: explaining risks of inflammatory bowel disease therapy to patients. *Aliment Pharmacol Ther.* 2011;33:23-32.
52. Levy LC, **Siegel CA.** Endoscopic mucosal healing in ulcerative colitis. *Aliment Pharmacol Ther.* 2011;33:1254-5.
53. **Siegel CA.** What options do we have for induction therapy for Crohn's disease? *Digestive Diseases* 2010;28:543-7.
54. **Siegel CA.** Should mucosal healing be a primary endpoint in clinical trials of Crohn's disease? *Pro. AGA Perspectives*, Oct/Nov 2010.
55. **Siegel CA.** Lost in translation: Helping patients understand the risks of inflammatory bowel disease therapy. *Inflamm Bowel Dis* 2010;16:2168.
56. **Siegel CA.** Creating quality measures in IBD. *Gastroenterology & Hepatology* 2010;6:218.
57. **Siegel CA.** Accidentally ASCENDING into comparative effectiveness research for inflammatory bowel disease; *Gastroenterology* 2009;137:1880.
58. **Siegel CA.** Risk of lymphoma in inflammatory bowel disease. *Gastroenterology and Hepatology* 2009;5(11):1.
59. **Siegel CA,** Marden S, Sands BE. *Response to:* Insufficient evidence to conclude whether anti-TNF therapy increases the risk of lymphoma in Crohn's disease. *Clin Gastroenterol and Hepatol* 2009;7:1139.
60. **Siegel CA,** Melmed GY, Ullman TA. Quality of care in inflammatory bowel disease: A STEEEP challenge. *Inflamm Bowel Dis.* 2009;16:134.
61. Johnson FR, Hauber AB, Ozdemir S, Hass S, **Siegel C,** Sands B. Quantitative benefit-risk tradeoff preferences for Crohn's disease treatments - Implications for regulatory decision making and disease management. *Int J Med Biol Front* 2009;15(5/6):457-466.
62. **Siegel CA,** Melmed GY. Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease. *Therapeutic Advances in Gastroenterology* 2009; 2:245.
63. **Siegel CA.** Making therapeutic decisions in IBD: The role of patients. *Current Opinion in Gastroenterology* 2009;25:334.
64. **Siegel CA,** Macdermott RP. Is chronic pain an extraintestinal manifestation of IBD? *Inflamm Bowel Dis.* 2009; 15:769.
65. Marden SM, **Siegel CA.** Give me prednisone and give me death. *Inflamm Bowel Dis.* 2009; 15:1119.
66. Sparrow MP, Irving PM, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Jones J, Kozuch PL, Melmed GY, Velayos FS, **Siegel CA.** Current controversies in Crohn's disease: A roundtable discussion of the BRIDGE group. *Gastroenterology & Hepatology* 2008; 4(10):713-720.

67. **Siegel CA.** Communicating the risks of inflammatory bowel disease medications to patients. *Inflamm Bowel Dis Monit*;2008(3):78-83.
68. **Siegel CA.** Patient perspectives on therapeutic options for IBD. *Gastroenterology and Hepatology* 2007; 3(12):909-911.
69. Hanauer SB, Kane SV, Plevy SE, **Siegel CA.** A case-based discussion of managing Crohn's disease: Integrating the new generation of anti-TNF α therapies. *Gastroenterology and Hepatology* 2007; 3(12):3-14.
70. **Siegel CA.** Guide to discussing the risks of immunomodulator and anti-TNF therapy with inflammatory bowel disease patients. *Practical Gastroenterology* 2007; XXXI (11): 14-24.
71. **Siegel CA.** Embracing the internet for progress in shared decision making. *Inflamm Bowel Dis* 2007;13(12):1579-1580.
72. Levy LC, **Siegel CA.** Adherence issues in the treatment of ulcerative colitis. *Medscape Internal Medicine.* Available at: <http://www.medscape.com/viewarticle/563408>
73. **Siegel CA,** Rubin DT. American College of Gastroenterology Annual Scientific Meeting 2006 Review. *Inflammatory Bowel Disease Monitor* 2007;7(3):121-124.
74. **Siegel CA,** Bensen, S, Ely P. Should rare complications of treatment influence decision-making in ulcerative colitis? *Inflammatory Bowel Diseases* 2007;13:242.
75. **Siegel, CA. Safe and Effective Use of Immunomodulators for Inflammatory Bowel Disease. Practical Gastroenterology 2006;7:31-44.**
76. **Siegel, CA.** As if mothers don't have enough to worry about...*Inflamm Bowel Dis.* 2006;12(2):146-147.
77. **Siegel CA,** Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. *Alimentary Pharmacology & Therapeutics* 2005;22 (1):1-16.
78. **Siegel CA,** Silas AE, Suriawinata AA, van Leeuwen DJ. Liver Biopsy 2005: When and How? *Cleveland Clinic Journal of Medicine* 2005;72(3):199-224.
79. **Siegel CA.** Take two prednisone and don't call me in the morning. *Inflamm Bowel Dis.* 2005;11(2):206-7.
80. **Siegel CA,** Book Review of *Gastrointestinal Symptoms in Advanced Cancer Patients.* *Journal of Palliative Care* 2004;7:89.
81. **Siegel CA,** Robertson DJ. Print and Media Review of *Gastroenterology and Hepatology for the Primary Care Provider: Principles, Practice and Guidelines for Referral.* *Gastroenterology* 2003;124:1160-1161.

Book Editor

1. Irving PM, **Siegel CA,** Rampton DS, Shanahan F, eds. *Inflammatory Bowel Disease: New Challenges (second edition).* 2011. Oxford: Wiley-Blackwell.

Book Chapters

1. Peterson TE, **Siegel CA** (2019). Risks and side effects of medical therapy. In: A Sturm, L White, eds. Inflammatory Bowel Disease Nursing Manual. (pp. 125-132). Cham, Switzerland: Springer Nature
2. Sands BE, **Siegel CA** (2015). Crohn's Disease. In: M Feldman, LS Friedman, LJ Brandt, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 10th edition (pp.1990-2022). Philadelphia: Saunders/Elsevier.
3. **Siegel CA** (2011). Balancing benefits and risks of biologic therapy. In: Bayless TM, Hanauer SB, eds. Advanced Therapy in Inflammatory Bowel Disease. (pp. 723-728). Shelton, Connecticut: People's Medical Publishing House.
4. **Siegel CA** (2011). The risks of immunomodulators and biologics: what should we tell patients? In: Irving PM, Siegel CA, Rampton DS, Shanahan F, eds. Inflammatory Bowel Disease: New Challenges. (pp. 140-143). Oxford: Wiley-Blackwell.
5. Korzenik JR, **Siegel, CA** (2011). The limitations of applying evidence based medicine to inflammatory bowel disease: what we do not learn from clinical trials. In: Lichtenstein G, ed. Ulcerative Colitis: The complete guide to medical management. (pp. 71-78). Thorofare: Slack incorporated.
6. Korzenik JR, **Siegel, CA** (2011). The limitations of applying evidence based medicine to inflammatory bowel disease: what we do not learn from clinical trials. In: Lichtenstein G, ed. Crohn's disease: The complete guide to medical management. (pp. 69-76). Thorofare: Slack incorporated.
7. Levy LC, **Siegel CA** (2011). State of the art medical treatment for the adult patient with IBD: The mesalamine based therapies. In: Cohen R, ed. Inflammatory bowel disease diagnosis and therapeutics – 2nd edition (pp. 59-71). New York: Humana Press.
8. Sands BE, **Siegel CA** (2010). Crohn's Disease. In: M Feldman, LS Friedman, LJ Brandt, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 9th edition (pp.1941-1973). Philadelphia: Saunders/Elsevier.
9. **Siegel CA** (2010). Comprehensive approach to patient risk. Risk versus benefit of biologics and immune suppressants. In: SR Targan, F Shanahan, LC Karp, eds. Inflammatory bowel disease: Translating basic science into clinical practice (pp. 678- 692). Oxford, UK: Wiley-Blackwell.
10. **Siegel CA** (2010). Risks and complications of biologic therapy. In: D Baumgart, ed. Biologic therapy for inflammatory bowel disease (pp. 64-73). Bremen: UNI-MED.
11. **Siegel CA**, Sands BE (2010). The first visit. In: SJ Bickston, RS Bloomfeld, eds. Handbook of inflammatory bowel disease (pp. 1-8). Baltimore: Wolters Kluwer/Lippincott Williams and Wilkins.
12. **Siegel CA** (2010). The risks of biologic therapy for inflammatory bowel disease. In: CN Bernstein, ed. The inflammatory bowel disease yearbook, volume 6 (pp.89-108). London, UK: Remedica.

13. Levy LC, **Siegel CA** (2009). What are the risks of biologic therapies and how do you communicate this to patients? In: DT Rubin, FA Farraye, S Friedman, eds. Curbside Consultations in Gastroenterology (pp. 27-32). Thorofare: Slack incorporated.
14. **Siegel CA** (2009). Inflammatory bowel disease in the current world: Controversies in Management. In: MC Dubinsky, EJ Scherl, eds. The life cycle and IBD: A focus on special populations (pp. 231-244). Thorofare: Slack incorporated.
15. Johnson FR, Hauber AB, Ozdemir S, Hass S. **Siegel CA**, Sands BE (2009). Quantitative benefit-risk tradeoff preference for Crohn's disease treatments – Implications for regulatory decision making and disease management. In: Crohn's disease: Etiology, Pathogenesis and Interventions. (pp. 457-466).
16. **Siegel CA**, Levy, LC (2009). What tips should I give my surgical colleagues who are seeing patients with pouchitis? In: Cash B, ed. Curbside consultation of the colon: 49 clinical questions. (pp. 133-135).

Honors & Awards

Endowed Professorship: Constantine and Joyce Hampers Profess or Medicine

Dartmouth-Hitchcock Department of Medicine Excellence in Teaching Award, 7-time awardee

New Hampshire Magazine Top Doctors, 2017-present

Inducted into Alpha Omega Alpha (AOA) Honor Medical Society, Geisel School of Medicine Chapter, 2017

America's Top Doctors, 9th Edition-present

American Journal of Gastroenterology Annual Lecturer, Orlando, FL, October 2017

Crohn's and Colitis Foundation Caring for a Cure Award, December 2016

American College of Gastroenterology, Best Abstract in Outcomes Research, ACG Annual Meeting 2016

Humanitarian of the Year, Crohn's and Colitis Foundation of America, New England Chapter, 2014

Inducted into the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) March 2013. <http://www.ioibd.org/>

Crohn's and Colitis Foundation of America (CCFA) Young IBD Investigator Award, May 2008. San Diego, CA

Research Excellence in GI and Liver (REGAL) Award recipient, October 2006, Chicago, IL



The 10th Annual Meeting of Asian Organization for Crohn's & Colitis
- Flash of Inspiration, and New Blow to IBD from Asia -

